ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Angel Bradley To Head NCAB Subcommittee UCLA, USC Join In CCRU Grant Application

September 3, 1982

NIH News: Board of Governors Appointed to Oversee Clinical Center

October 24, 1996

RFA On etiology Of AIDS, Kaposi’s

June 3, 1983

In Brief: ONS Invites Proposals For Research On Hazards Of Chemotherapy; UTSCC Adopts Code Of Ethics

August 31, 1984

In Brief: US Pharmacopeia Names Advisory Panel For Hematologic And Oncological Disease

May 31, 1996

DCPC Advisors Okay Continuation of Children’s Diet Study

January 31, 1992